SIGLEC1 and systemic sclerosis: The objective of the present study was to assess whether the expression of SIGLEC-1 on CD14+ cells via flow cytometry could serve as a useful biomarker for disease manifestation, including pulmonary or vascular complications and therapeutic response in SSc.